skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

US_Shutdown_Pharma

 

Another ANDA bolus is coming, although not because of a new US FDA policy or assessment time change.

If generic drug sponsors adhere to historical averages, the total number of applications processed upon the end of the government shutdown could be among the largest in a single month of the GDUFA era. Applications received in December 2018 and January and February 2019 could total 300 or more, based on a Pink Sheet analysis of historical ANDA submission figures. (See chart below.)

Since the shutdown began, FDA has not been allowed to accept applications that require a fiscal year 2019 user fee payment, which includes ANDAs.

Many already may be sitting in FDA's electronic gateway, but will not be officially received until after the shutdown ends, meaning assessment staff cannot begin working on them. The result is a growing pot of applications that will reach the agency all at once, pressuring assessment staff when they return to work.

December typically is among the busiest months of the year for ANDA submissions, as companies work to close out their generic drug portfolios before the end of the calendar year. Sponsors have submitted on average about 163 ANDAs in December since the generic drug user fee program launched in October 2012.

January and February tend to see lighter submission volume, in part because of the December rush. Sponsors have sent the agency about 60 ANDAs in January and another 55 in February on average.

The combined average of about 278 ANDAs would be the second-largest bolus received in a single month in the GDUFA era, although it may be divided between pre- and post-shutdown receipts. FDA received ANDAs for three weeks in December, but has not yet reported that figure. The dates sponsors sent ANDAs that month would affect the number awaiting assessment.

The combined bolus also may be much higher than the three-month average. Submission totals during fiscal year 2015 were down substantially after sponsors submitted 635 applications in June 2014 to avoid new stability requirements about to go into effect. (Also see "ANDA Avalanche: How Will FDA Deal With The 600 Received This Month?" - Pink Sheet, 30 Jun, 2014.)

If FY 2015 figures are disregarded as outliers, the submission average for the December to February period jumps to more than 313.

Robert Pollock, senior adviser and outside director to the board at Lachman Consultants, told the Pink Sheet that in his opinion (not based on information from FDA) a 300-plus ANDA bolus is possible. Pollock said many December ANDAs tend to be submitted near the end of the month, meaning they could have arrived after the shutdown began.

The March Bolus Also Is Approaching

If the shutdown lingers through February, the bolus also could merge with the traditional March rush, further escalating the pressure on the agency.

The March average submission total is about 118. Spikes tend to occur then as Indian generics firms send submissions before closing out their fiscal year. (Also see "Generic Drug Puzzle: Why Did ANDA Submissions Spike Again?" - Pink Sheet, 11 Apr, 2017.)

Overall, ANDA submissions tend to follow a yo-yo pattern – a busy month is followed by several down months. (See chart below.)

December 2016 now stands as the second-highest total, when 235 ANDAs were submitted. FDA had recently implemented its 10-month ANDA assessment goal, which may have helped increase the volume. (Also see "ANDA Stress Test: End-Of-Year Submission Bolus Pressures US FDA Review System" - Pink Sheet, 9 Jan, 2017.)

Sponsors submitted 216 ANDAs in September 2017 in part to avoid paying a substantially higher user fee when the new fiscal year started the next month. (Also see "There's The Bolus! ANDA Sponsors Race To Avoid User Fee Spike" - Pink Sheet, 9 Oct, 2017.)

Will Shutdown Bolus Affect Assessment Goals?

The shutdown bolus will serve as a big stress test for FDA's Office of Generic Drugs and its ability to meet its assessment goals.

All the applications filed during the shutdown may receive the same filing date for administrative purposes, which could spark clashes if that leads to shared 180-day exclusivity awards. (Also see "US Federal Courts Can Operate Until Jan. 25; Patent Office Faces Eminent Closure Under Shutdown" - Pink Sheet, 16 Jan, 2019.)

Some likely will not clear the initial filing assessment, but OGD still may be assessing hundreds of ANDAs with 10-month assessment goals about the same time.

Pollock said OGD has never seen this many ANDAs with similar goals since the program launched. He predicted a "wild ride" in a blog post on the subject.

"They have not had a huge single submission month with the 10-month review clock," he said in an email to the Pink Sheet. "I believe it will certainly put a strain on the program to be able to meet all of the GDUFA review goals if the number is well north of 200 [submissions]."

The Association for Accessible Medicines, a generic drug trade association, told the Pink Sheet that it does not see the upcoming submissions bolus and subsequent review goals as an issue "at this point in time" and said special measures to handle it are not a consideration.

FDA responded that it had no information to share.

Indeed, no special measures were implemented to handle the June 2014 bolus, but those applications also were not subject to formal review goals under GDUFA.

At the same time, OGD Director Kathleen Uhl is expected to retire in February, meaning the staff will be adjusting to a new permanent or acting director. (Also see "US FDA Generic Drug Office Director Uhl Announces Retirement" - Pink Sheet, 17 Jul, 2018.)

FDA's generics staff continues to work during the shutdown, but only on applications that were already in-house when the so-called "lapse period" began or do not require a user fee payment. They are supported by carryover user fee revenue, which FDA says will last for several more months. (Also see "US FDA Shuttering More Operations As User Fee Money Dwindles" - Pink Sheet, 23 Jan, 2019.)

The agency now is approving more ANDAs per day during the shutdown than in the three weeks preceding it in December. (Also see "Shutdown Week Four: FDA Maintains Pre-Shutdown Output Pace In Some Cases" - Pink Sheet, 14 Jan, 2019.)

 

Read also

  • In Vivo: strategic insights for life sciences decision-maker...

    Pharma News and Healthcare Business Insights

    Pharma Intelligence offers a wealth of pharmaceutical industry news and strategic insight into the healthcare & biotechnology markets from around the world. Working in an interconnected global network, our 65 journalists and over 300 in-house analysts supply comprehensive analysis and reports.

  • Pink Sheet: global policy and regulatory coverage

    Cancer Immunotherapy: When To Stop Treatment Remains Unanswered Question

    02 Aug 2017

    Long-term or open-ended treatment with PD-1/PD-L1 inhibitors is a burden for patients and the healthcare system and does not fit the biological paradigm of cancer immunotherapies, experts say; however, challenges to studying shorter durations include fears of undertreatment and patient objections to stopping a therapy that appears to be working.

    Topics Clinical trials

  • Medtech Insight: global medical technology news & analysis

    UK Notified Body BSI Sets Out Clear Post-Brexit Paths As It Goes Dutch

    BSI tackles Brexit issues head-on with aim to allay fears and bring clarity while UK regulator, MHRA, remains reticent to do so. Its messages are relevant for all doing business in the UK

    Topics Brexit

;

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: